Part 1: Screening 23,000 advanced or incurable cancer patients
Screening of up to 23,000 advanced or incurable cancer patients using Comprehensive Genomic Profiling (CGP) at no cost to the patient.
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour and we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.
The genomic profiling is carried out by NATA accredited pathology laboratories at no cost to the patient.
A team of our experts review the genomic profile of the tumour with other clinical and patient information. A Molecular Oncology Board (MOB) Report provides information to treating doctors, including potential trials for patients. A copy of the genomic profiling pathology report, is also provided to the referring clinician.
The process can take between 8 – 10 weeks – from when a patient has provided written consent to participate, to when a report is provided back to the referring clinician.
Part 2: An Observational Cohort Study of people enrolled in CaSP
CaSP does not deliver any specific intervention and is not a clinical trial. Its primary purpose is to make Comprehensive Genomic Profiling (CGP) more broadly available to people with an unmet need and to use that information to link people to potential clinical trials.
It is important that the information collected by CaSP be used to guide how CGP is implemented in Australia and to evaluate what use it provides to the community.
Part 3: Research Registry and Biobank
CaSP will establish a research registry and bioresource to facilitate the Observational cohort study and provide a resource for future use including clinical trial and treatment matching, and epidemiological and public health research studies to facilitate ongoing research into cancer and its treatment.
